These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 24198624

  • 1. Update and critical appraisal of sevelamer in the management of chronic renal failure.
    Grinfeld J, Inaba A, Hutchison AJ.
    Open Access J Urol; 2010 Sep 02; 2():161-70. PubMed ID: 24198624
    [Abstract] [Full Text] [Related]

  • 2. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
    Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL.
    Drugs; 2008 Sep 02; 68(1):85-104. PubMed ID: 18081374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA, Shepler BM.
    Pharmacotherapy; 2010 Jul 02; 30(7):741-8. PubMed ID: 20575637
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
    Assimon MM, Mousa S, Shaker O, Pai AB.
    Consult Pharm; 2010 Jan 02; 25(1):41-54. PubMed ID: 20211816
    [Abstract] [Full Text] [Related]

  • 7. Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.
    Nadin C.
    Core Evid; 2005 Jan 02; 1(1):43-63. PubMed ID: 22496676
    [Abstract] [Full Text] [Related]

  • 8. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
    Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E.
    Am J Kidney Dis; 1999 Apr 02; 33(4):694-701. PubMed ID: 10196011
    [Abstract] [Full Text] [Related]

  • 9. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
    Nolan CR, Qunibi WY.
    Kidney Int Suppl; 2005 Jun 02; (95):S13-20. PubMed ID: 15882308
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ.
    Saudi Med J; 2004 Jun 02; 25(6):785-91. PubMed ID: 15195212
    [Abstract] [Full Text] [Related]

  • 11. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L, Bernard LM, Elder GJ.
    Clin J Am Soc Nephrol; 2016 Feb 05; 11(2):232-44. PubMed ID: 26668024
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
    Nagano N, Fukushima N.
    Nihon Yakurigaku Zasshi; 2003 Nov 05; 122(5):443-53. PubMed ID: 14569164
    [Abstract] [Full Text] [Related]

  • 15. Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
    St Peter WL, Fan Q, Weinhandl E, Liu J.
    Clin J Am Soc Nephrol; 2009 Dec 05; 4(12):1954-61. PubMed ID: 19833904
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR.
    Kidney Int Suppl; 2005 Jul 05; (96):S7-14. PubMed ID: 15954948
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E.
    Am J Kidney Dis; 1997 Jan 05; 29(1):66-71. PubMed ID: 9002531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.